Document is current
Any future updates will be listed below
-
Authors
He, Yonghan https://orcid.org/0000-0003-4409-4590
Zhang, Xuan https://orcid.org/0000-0001-6062-6708
Chang, Jianhui
Kim, Ha-Neui https://orcid.org/0000-0003-2498-6700
Zhang, Peiyi
Wang, Yingying
Khan, Sajid https://orcid.org/0000-0003-1331-8846
Liu, Xingui
Zhang, Xin
Lv, Dongwen https://orcid.org/0000-0003-4677-8996
Song, Lin
Li, Wen
Thummuri, Dinesh
Yuan, Yaxia
Wiegand, Janet S.
Ortiz, Yuma T.
Budamagunta, Vivekananda
Elisseeff, Jennifer H.
Campisi, Judith
Almeida, Maria
Zheng, Guangrong https://orcid.org/0000-0002-8106-6663
Zhou, Daohong https://orcid.org/0000-0002-2400-6461
-
Funding
Funding for this research was provided by:
NIH
- License Information
-
More Information
Article History
Received: 14 February 2019
Accepted: 27 March 2020
First Online: 24 April 2020
Competing interests
: X.Z., J.C., Y.W., G.Z., and D.Z. are inventors of a pending patent application for use of Bcl-xl PROTACs as senolytic agents. J.C. and D.Z. are co-founders and stockholders of Unity Biotechnology that develops senolytics to treat age-related diseases. J.H.E. is an advisor and stockholder of Unity Biotechnology. The other authors declare no competing interests.
